Compare e l f Beauty Inc (ELF) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs Zimmer Biomet Holdings Inc — how do they compare? e l f Beauty Inc trades at $108.03 (market cap $6.25B), while Zimmer Biomet Holdings Inc trades at $89.8 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.7× e l f Beauty Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 25 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| ELF | ZBH | |
|---|---|---|
Market Cap | $6.25B | $16.95B |
Volume | 1,099,552 | 2,505,240 |
Sector | Consumer Staples | Health |
52-Week High | $144.97 | $103.98 |
52-Week Low | $49.57 | $79.58 |
Typical Hold Time | 25 Days | 89 Days |
Enterprise Value | $6.84B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF trades at $105.03, up 2.18% today, with a bullish technical signal from moving averages and strong recent earnings beats. The company shows robust revenue growth, expanding internationally with the rhode brand launch in Europe via Sephora, though net margins are thin at 3.38%. Valuation ratios are elevated with a P/E of 108.12, reflecting high growth expectations. Analyst consensus is mixed with a 48.27% buy rating but a price target of $95.91 below the current price.
Outlook: ELF's aggressive marketing and global expansion present growth opportunities, but the stock's premium valuation and high P/E pose risks if growth slows. Investor sentiment is cautiously optimistic, supported by institutional buying, yet overbought RSI levels suggest near-term volatility. Key risks include execution of international strategy and competitive pressures in the beauty sector.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
